Melanoma antigen recognition by tumour-infiltrating T lymphocytes (TIL): Effect of differential expression of Melan-A/MART-1

Clinical and Experimental Immunology

Volumn 119, Issue 1, 2000, Pages 11-18

  Ramirez Montagut, T ^a   Andrews, D M ^a   Ihara, A ^a   Pervaiz, S ^a   Pandolfi, F ^a,b   Van Den Elsen, P J ^a,c   Waitkus, R ^a   Boyle, L A ^a   Hishii, M ^a   Kurnick, J T ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b CATHOLIC UNIVERSITY   (Italy)

^c LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Cytotoxic T lymphocytes; Melan A MART 1; Melanoma; PCR SSCP; T cell receptor; Tumour infiltrating lymphocytes

Indexed keywords

HLA ANTIGEN; MELAN A; MONOCLONAL ANTIBODY; T LYMPHOCYTE RECEPTOR; UNCLASSIFIED DRUG;

ANTIGEN EXPRESSION; ANTIGEN RECOGNITION; ARTICLE; CELL DENSITY; CONTROLLED STUDY; HLA TYPING; HUMAN; HUMAN CELL; HUMAN TISSUE; MELANOMA; MOLECULAR CLONING; NUCLEOTIDE SEQUENCE; PHENOTYPE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; TUMOR ASSOCIATED LEUKOCYTE;

AMINO ACID SEQUENCE; ANTIGENS, NEOPLASM; BASE SEQUENCE; CLONE CELLS; CYTOTOXICITY, IMMUNOLOGIC; DNA; GENE EXPRESSION; HUMANS; LYMPHOCYTES, TUMOR-INFILTRATING; MELANOMA; MOLECULAR SEQUENCE DATA; NEOPLASM PROTEINS; PHENOTYPE; POLYMORPHISM, SINGLE-STRANDED CONFORMATIONAL; RECEPTORS, ANTIGEN, T-CELL, ALPHA-BETA; TUMOR CELLS, CULTURED;

EID: 0033964884     PISSN: 00099104     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2249.2000.01089.x     Document Type: Article

References (46)

1. 1 Itoh K, Platsoucas C, Balch C. Autologous tumor-specific cytotoxic T lymphocytes in the infiltrate of human melanomas. J Exp Med 1988; 168:1419-41.
2. 2 Pandolfi F, Boyle L, Trentin L, Oliva A, Kurnick J. T cell receptor gene rearrangement and cytotoxic activities of clones isolated from tumor infiltrating lymphocytes from melanoma patients. Clin Exp Immunol 1994; 95:141-7.
3. 3 Kawakami Y, Rosenberg S, Lotze M. Interleukin 4 promotes the growth of tumor-infiltrating lymphocytes cytotoxic for human autologous melanoma. J Exp Med 1988; 168:2183-91.
4. 4 Mackensen A, Ferradini L, Carcelain G, Triebel F, Faure F, Viel S, Hercend T. Evidence for in situ amplification of cytotoxic T-lymphocytes with antitumor activity in a human regressive melanoma. Cancer Res 1993; 53:3569-73.
5. 5 Sensi M, Traversari C, Radrizzani M et al. Cytotoxic T-lymphocyte clones from different patients display limited T-cell-receptor variable-region gene usage in HLA-A2-restricted recognition of the melanoma antigen Melan-A/MART-1. Proc Natl Acad Sci USA 1995; 92:5674-8.
6. 6 Peoples G, Davey M, Goedegebuure P, Schoof D, Eberlein T. T cell receptor V beta 2 and V beta 6 mediate tumor-specific cytotoxicity by tumor-infiltrating lymphocytes in ovarian cancer. J Immunol 1993; 151:5472-80.
7. 7 Boon T, Cerottini J, Van den Eynde B, Van der Bruggen P, Van Pel A. Tumor antigens recognized by T lymphocytes. Ann Rev Immunol 1994; 12:337-65.
8. 8 Kawakami Y, Eliyahu S, Delgado C et al. Cloning of the gene coding for a shared human melanoma antigen recognized by autologous T cells infiltrating into tumor. Proc Natl Acad Sci USA 1994; 91:3515-9.
9. 9 Bakker A, Schreurs M, De Boer A, Kawakami Y, Rosenberg S, Adema G, Figdor C. Melanocyte lineage-specific antigen gp100 is recognized by melanoma-derived tumor-infiltrating lymphocytes. J Exp Med 1994; 179:1005-9.
10. 10 Kawakami Y, Eliyahu S, Sakaguchi K et al. Identification of the immunodominant peptides of the MART-1 human melanoma antigen recognized by the majority of HLA-A2-restricted tumor infiltrating lymphocytes. J Exp Med 1994; 180:347-52.
11. 11 Wolfel T, Van Pel A, Brichard V, Schneider J, Seliger B, Meyer Zum Buschenfelde K, Boon T. Two tyrosinase nonapeptides recognized on HLA-A2 melanomas by autologous cytolytic T lymphocytes. Eur J Immunol 1994; 24:759-64.
12. 12 Robbins P, El-Gamil M, Kawakami Y, Stevens E, Yannelli J, Rosenberg S. Recognition of tyrosinase by tumor-infiltrating lymphocytes from a patient responding to immunotherapy. SO Cancer Res 1994; 54:3124-6.
13. 13 Bakker A, Schreurs M, Tafazzul G, De Boer A, Kawakami Y, Adema G, Figdor C. Identification of a novel peptide derived from the melanocytespecific gp100 antigen as the dominant epitope recognized by an HLA-A2.1-restricted anti-melanoma CTL line. Int J Cancer 1995; 62:97-102.
14. 14 Kawakami Y, Eliyahu S, Jennings C et al. Recognition of multiple epitopes in the human melanoma antigen gp100 by tumor-infiltrating T lymphocytes associated with in vivo tumor regression. J Immunol 1995; 154:3961-8.
15. 15 Hishii M, Andrews D, Boyle L, Wong J, Pandolfi F, Van den Elsen P, Kurnick J. Accumulation of the same anti-melanoma T cell clone in two different metastatic sites. Proc Natl Acad Sci USA 1997; 94:1378-83.
16. 16 Castelli C, Storkus W, Maeurer M et al. Mass spectrometric identification of a naturally processed melanoma peptide recognized by CD8+ cytotoxic T lymphocytes. J Exp Med 1995; 181:363-8.
17. 17 Kawakami Y, Rosenberg SA. Immunobiology of human melanoma antigens MART-1 and gp100 and their use for immuno-gene therapy. Int Rev Immunol 1997; 14:173-92.
18. 18 Rivoltini L, Loftus DJ, Squarcina P et al. Recognition of melanoma-derived antigens by CTL: possible mechanisms involved in downregulating anti-tumor T-cell reactivity. Crit Rev Immunol 1998; 18:55-63.
19. 19 Dufour E, Carcelain G, Gaudin C, Flament C, Avril MF, Faure F. Diversity of the cytotoxic melanoma-specific immune response: some CTL clones recognize autologous fresh tumor cells and not tumor cell lines. J Immunol 1997; 158:3787-95.
20. 20 Maeurer MJ, Gollin SM, Martin D et al. Tumor escape from immune recognition: lethal recurrent melanoma in a patient associated with downregulation of the peptide transporter protein TAP-1 and loss of expression of the immunodominant MART-1/Melan-A antigen. J Clin Invest 1996; 98:1633-41.
21. 21 Jager E, Ringhoffer M, Altmannsberger M et al. Immunoselection in vivo: independent loss of MHC class 1 and melanocyte differentiation antigen expression in metastatic melanoma. Int J Cancer 1997; 71:142-7.
22. 22 Marincola FM, Hijazi YM, Fetsch P et al. Analysis of expression of the melanoma-associated antigens MART-1 and gp100 in metastatic melanoma cell lines and in in situ lesions. J Immunother Emphasis Tumor Immunol 1996; 19:192-205.
23. 23 Lehmann F, Marchand M, Hainaut P et al. Differences in the antigens recognized by cytolytic T cells on two successive metastases of a melanoma patient are consistent with immune selection. Eur J Immunol 1995; 25:340-7.
24. 24 Topalian S, Kasid A, Rosenberg S. Immunoselection of a human melanoma resistant to specific lysis by autologous tumor-infiltrating lymphocytes. Possible mechanisms for immunotherapeutic failures. J Immunol 1990; 144:4487-9.
25. 25 Kurnick J, Kradin R, Blumberg R, Schneeberger E, Boyle L. Functional characterization of T lymphocytes propagated from human lung carcinomas. Clin Immunol Immunopathol 1986; 38:367-80.
26. 26 Kradin R, Kurnick J, Gifford J, Pinto C, Preffer F, Lazarus D. Adoptive immunotherapy with interleukin-2 (IL-2) results in diminished IL-2 production by stimulated peripheral blood lymphocytes. J Clin Immunol 1989; 9:378-85.
27. 27 Kurnick J, Gronvik K, Kimura A, Lindblom J, Skoog V, Sjoberg O, Wigzell H. Long term growth in vitro of human T cell blasts with maintenance of specificity and function. J Immunol 1978; 122:1255.
28. 28 Kurnick J, Hayward A, Altevogt P. Helper and suppressor/inducer activity of human T cells and their cloned progeny maintained in longterm culture. J Immunol 1981; 126.1307.
29. 29 Stegagno M, Boyle L, Preffer F, Leary C, Colvin R, Cosimi A, Kurnick J. Functional analysis of T cell subsets and clones in human renal allograft rejection. Transplant Proc 1987; 19:394-7.
30. 30 Pandolfi F, Boyle LA, Trentin L, Kurnick JT, Isselbacher KJ, Gattoni Celli S. Expression of HLA-A2 antigen in human melanoma cell lines and its role in T-cell recognition. Cancer Res 1991; 51:3164-70.
31. 31 Ordonez N, Xialong J, Hickey R. Comparison of HMB-45 monoclonal antibody and S-100 protein in the immunohistochemical diagnosis of melanoma. Am J Clin Pathol 1988; 90:385-90.
32. 32 Gaugler B, Van den Eynde B, Van der Bruggen P et al. Human gene MAGE-3 codes for an antigen recognized on a melanoma by autologous cytolytic T lymphocytes. J Exp Med 1994; 179:921-30.
33. 33 Chen Y, Stockert E, Jungbluth A, Tsang S, Coplan K, Scanlan M, Old L. Serological analysis of Melan-A (MART-1), a melanocyte-specific protein homogeneously expressed in human melanomas. Proc Natl Acad Sci USA 1996; 93:5915-9.
34. 34 Struyk L, Kurnick J, Hawes G et al. T-cell receptor V-gene usage in synovial fluid lymphocytes of patients with chronic arthritis. Hum Immunol 1993; 37:237-51.
35. 35 Chomczynski P, Sacchi N. Single-step of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 1987; 162:156.
36. 36 Sanger F, Nicklen S, Coulson A. DNA sequencing with chain-terminating inhibitors. Proc Natl Acad Sci USA 1977; 74:5463-7.
37. 37 Hayashi K. PCR-SSCP: a method for detection of mutations. Gen Anal Tech Appl 1992; 9:73-9.
38. 38 Hayashi K, Yandell D. How sensitive is PCR-SSCP? Human Mutation 1993; 2:338-46.
39. 39 Ferradini L, Roman-Roman S, Azocar J, Avril M, Viel S, Triebel F, Hercend T. Analysis of T-cell receptor alpha/beta variability in lymphocytes infiltrating a melanoma metastasis. Cancer Res 1992; 52:4649-54.
40. 40 Shilyansky J, Nishimura M, Yannelli J, Kawakami Y, Jacknin L, Charmley P, Rosenberg S. T-cell receptor usage by melanoma-specific clonal and highly oligoclonal tumor-infiltrating lymphocyte lines. Proc Natl Acad Sci USA 1994; 91:2829-33.
41. 41 Puisieux I, Even J, Pannetier C, Jotereau F, Favrot M, Kourilsky P. Oligoclonality of tumor-infiltrating lymphocytes from human melanomas. J Immunol 1994; 153:2807-18.
42. 42 ThorStraten P, Becker JC, Seremet T, Brocker EB, Zeuthen J. Clonal T cell responses in tumor infiltrating lymphocytes from both regressive and progressive regions of primary human malignant melanoma. J Clin Invest 1996; 98:279-84.
43. 43 Sensi M, Castelli C, Anichini A, Grossberger D, Mazzocchi A, Mortarini R, Parmiani G. Two autologous melanoma-specific and MHC-restricted human T cell clones with identical intra-tumor reactivity do not share the same TCR V alpha and V beta gene families. Melanoma Res 1991; 1:261-71.
44. 44 DeVries T, Fourkour A, Wobbes T, Verkroost G, Ruiter DJ, VanMuijen G. Heterogeneous expression of immunotherapy candidate proteins gp100, MART-1, and tyrosinase in human melanoma cell lines and in human melanocytic lesions. Cancer Res 1997; 57:3223-9.
45. 45 Mihm M, Clemente C, Cascinelli N. Tumor infiltrating lymphocytes in lymph node melanoma metastases: a histopathologic prognostic indicator and an expression of local immune response. Lab Invest 1996; 74:43-7.
46. 46 Day CJ, Mihm MJ, Lew R et al. Prognostic factors for patients with clinical stage 1 melanoma of intermediate thickness (1.51-3.99 mm). Ann Surg 1982; 1:35-43.